This committee planned the questions on the basis of the findings from the scoping review and identified seven experts [10]three endocrinologists, two cardiologists, and two nephrologistschosen according to their expertise in treating people with diabetes and their experience in formulating local guidelines or leading the implementation of policies within the healthcare system
James Chao, a board-certified physician specializing in medical weight loss and co-founder of VedaNu Wellness, notes that patients who lose weight without dietary guidance can lose between 15% and 40% of that weight from lean body mass
This approach should be discussed with a healthcare provider to ensure the dose remains therapeutically meaningful
However, similar to GLP-1RAs, these agents may induce gastrointestinal adverse effects including anorexia and gastrointestinal discomfort.222 Despite these concerns, such drugs have demonstrated beneficial effects in lowering the incidence of major cardiovascular events and strokes.223 Pharmacokinetically, GLP-1RAs and GLP-1/GIP dual agonists display distinct profiles attributable to their structural heterogeneity, with extended half-lives potentially correlating with an increased risk of adverse events.224 Consequently, vigilant monitoring of patient responses is imperative during treatment, particularly when these agents are administered concomitantly with other medications, to ensure both safety and therapeutic efficacy
Interpretation should consider sex-specific reference ranges and assay variability
is a named inventor on patents that cover GLP-1, GIP, or dual GLP-1/GIP receptor agonists as treatments for AD and PD
